ロード中...

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses characterized the population pharmacokinetics of upa...

詳細記述

保存先:
書誌詳細
出版年:Clin Pharmacokinet
主要な著者: Klünder, Ben, Mittapalli, Rajendar K., Mohamed, Mohamed-Eslam F., Friedel, Anna, Noertersheuser, Peter, Othman, Ahmed A.
フォーマット: Artigo
言語:Inglês
出版事項: Springer International Publishing 2019
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6614152/
https://ncbi.nlm.nih.gov/pubmed/30945116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00739-3
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!